Our findings showed that ICM treatment inhibited the phosphorylation of constitutively activated STAT3, suggesting that targeting the nucleo-cytoplasmic translocation of HMGB1 may offer a potential therapeutic strategy against cancers with constitutive STAT3 activation. Here, STAT3 is linked to cancer.